SHARE PRICE: 1255.00 GBX
Log in Log in Demo Demo
The Craneware Group The Craneware Group
The Craneware Group The Craneware Group
  • Solutions

    Solutions

    Our applications and industry-leading team of experts contextualize operational, financial, and clinical data, providing insights that clearly demonstrate realistic revenue integrity and 340B compliance opportunities for our customers.

    Learn More Learn More
    • Solutions
    • Pricing
      • Pricing
      • Trisus Pricing Transparency
      • Trisus Pricing Analyzer
    • Revenue
      • Revenue
      • Trisus Chargemaster
      • Insight Medical Necessity
      • Trisus Claims Informatics
      • Appeals Services
      • Trisus Supply
      • Trisus Supplies Assistant
      • InSight Audit
      • InSight Denials
    • Cost & Decision Support
      • Cost & Decision Support
      • Trisus Decision Support
      • Trisus Medication Analytic Solutions
      • Trisus Supply
      • Trisus Supplies Assistant
    • 340B & Pharmacy
      • 340B & Pharmacy
      • Sentinel
      • Sentrex
      • Sentrex 330
      • Referral Verification System (Sentrex)
      • Referral Verification System (Senturion)
      • Trisus Medication Analytic Solutions
      • Senturion Professional Service
      • Sentry Core
    • Services
      • Services
      • Professional Services Catalogue
      • Appeals Services
    • Trisus
  • News & Events

    News & Events

    Read the latest news and learn about upcoming training and events with our industry leading experts.

    News & Events News & Events
    • News & Events
    • Press Releases
    • Events
    • 340B Coalition Winter Conference
    • Summit
  • Resources

    Resources

    Stay current on thought leadership news and events using with these online resources.

    View Our Publications View Our Publications
    • Resources
    • COVID-19
    • Publications
    • Success Stories
    • Webinars
    • Blogs
  • Company

    Company

    The Craneware Group is recognized as the leading provider of Revenue integrity and 340B management solutions that improve financial performance in the US hospital and health system markets. We’re respected as a healthcare business partner delivering value, quality, and outstanding customer service.

    Our Story Our Story
    • Company
    • Our Story
      • Our Story
      • Values
    • Governance
    • Investors
      • Investors
      • Why Invest
      • Reports
      • Investor Contacts
      • Shareholder Centre
      • AIM Rule 26
      • Advisors
      • AIM securities information
    • Careers
      • Careers
      • Culture
      • Join
    • ESG
    • Leadership
    • Board of Directors
Craneware
Log in Log in Demo Demo
SHARE PRICE: 1255.00 GBX
Craneware

COVID-19

  • Home
  • Resources

COVID-19 (novel Coronavirus) Billing, Coding, and Compliance Updates

The media is closely reporting on efforts being taken across the United States to ramp up clinical operations to prepare for and respond to the influx of patients that will require specialized testing and treatment. Likewise, healthcare organizations are taking steps to create resiliency across financial operations to support their missions in the months to come. Your efforts are critically important.

The Craneware Group’s data team is continuously monitoring guidance regarding billing and coding for COVID-19 testing and treatment.

The Craneware Group customers and non-customers alike should feel free to contact [email protected] for questions related to COVID-19 billing and coding.

  • 12/12/2022
    Are there changes to bivalent COVID-19 vaccines for children?
    View press release
  • 11/17/2022
    Has the AMA announced new CPT codes for the Moderna bivalent booster dose?
    View press release
  • 11/03/2022
    Is the CPT code for the administration of the Novavax Adjuvanted booster recognized by Medicare?
    View press release
  • 10/31/2022
    Is there now an effective date available for the pediatric bivalent Moderna and Pfizer COVID-19 vaccine booster doses?
    View press release
  • 10/18/2022
    Did the FDA amend the Emergency Use Authorizations for the Moderna and Pfizer COVID-19 vaccine booster doses?
    View press release
The Craneware Group

Solutions

  • Pricing
  • Revenue
  • Cost
  • 340B & Pharmacy
  • Services
  • Trisus

News & Events

  • Press Releases

Resources

  • COVID-19
  • Publications

Company

  • Our Story
  • Governance
  • Investors
  • Careers
  • ESG

Follow us

  • Twitter
  • LinkedIn
© The Craneware Group. All rights reserved.
  • Security Statement
  • Privacy Policy
  • Legal
  • Modern Slavery Statement
  • Contact
  • Sitemap
  • Cookie Settings